Developer docs
API playgroundTry for free, no card

Search company profiles

AviadoBio

Full company profile

uuid0000a24

Namestring
AviadoBio
Legal namestring
AviadoBio Limited
Websiteurl
aviadobio.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

AviadoBio is a London-headquartered, clinical-stage gene therapy company founded in 2019 to develop one-time, disease-modifying AAV-based treatments for neurodegenerative disorders with high unmet need. The company was spun out of King's College London and the UK Dementia Research Institute and operates with 11–50 employees across the UK and the United States. Its pipeline is anchored by AVB-101, an AAV gene supplementation therapy delivered via minimally invasive intrathalamic infusion that is currently in Phase 1/2 development (ASPIRE-FTD trial) for frontotemporal dementia with GRN mutations (FTD-GRN), and extends into AVB-406 (vMiX™ RNAi silencing of MAPT for Alzheimer's disease and tauopathies, preclinical with planned 2026 clinical entry), UGX-202 (an optogenetic AAV gene therapy for retinitis pigmentosa licensed from UgeneX Therapeutics in October 2025), and AVB-205 (an ATXN2-targeting preclinical construct for ALS).

AviadoBio's core technology is the proprietary vMiX™ vectorized RNAi gene silencing platform, exclusively licensed from King's College London and expanded in June 2026 to cover all human therapeutic areas. vMiX combines AAV-delivered RNAi payloads with cell- and tissue-specific promoters to enable one-time, durable silencing of up to three genes and supports silencing-and-replacement constructs. Delivery innovation includes the intrathalamic approach (leveraging the thalamus as a CNS relay hub for broad cortical expression of progranulin) and a BBB-penetrant AAV capsid using the human transferrin receptor 1 for systemic CNS exposure in AVB-406.

The company is pre-revenue and has no commercial products; its near-term economic model rests on milestone-based licensing and partnerships rather than product sales. Capital is sourced from an $80M seed round (December 2021), a $20M equity investment plus up to $30M upfront from Astellas under a now-lapsed exclusive option for AVB-101, strategic grants from the Alzheimer's Drug Discovery Foundation and the Association for Frontotemporal Degeneration, and contingent milestone payments from the UgeneX UGX-202 deal worth up to $413M. Go-to-market is enterprise-led: a Phase 1/2 clinical trial operating at multiple international sites, scientific-conference-driven visibility (ASGCT, AAIC, ESGCT, ISFTD), and a stated intent to pursue strategic partnerships to advance vMiX-enabled programs into cardiovascular, nephrology, oncology, and other newly licensed therapeutic areas.

Short descriptiontext

AviadoBio is a London-based clinical-stage gene therapy company developing one-time AAV-based treatments for neurodegenerative disorders, including AVB-101 in Phase 1/2 for FTD-GRN, leveraging its proprietary vMiX RNAi silencing platform licensed from King's College London.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV gene therapy, neurodegenerative disease treatment, RNAi gene silencing, frontotemporal dementia therapy, central nervous system delivery
Industry3 codes
PRIMARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Computer Systems Design and Related Services54151
Product category
Gene Therapy for Neurodegenerative Diseases
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Gene Therapy Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, AviadoBio is developing gene therapies for neurodegenerative diseases. The company has received strategic investments from ADDF and AFTD, and previously had an exclusive option agreement with Astellas worth up to $2.18 billion plus royalties. Revenue will come from commercialization of approved gene therapies.

fiercebiotech.com
2Platform Licensing and Partnerships
TypeLicensing Royalties
Description

Expanded vMiX platform license with King's College London enables strategic collaborations and partnerships across cardiovascular disease, nephrology, oncology and other indications beyond the company's core neuroscience focus.

aviadobio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1vMiX™
Description

Proprietary vectorized RNA interference (RNAi) gene silencing platform for one-time, durable gene silencing using AAV delivery

aviadobio.com
Core offering1 text field

AviadoBio is a clinical-stage gene therapy company developing investigational AAV-based, one-time gene therapies for neurodegenerative diseases. Its lead program, AVB-101, delivers a functional GRN gene via intrathalamic infusion for frontotemporal dementia with GRN mutations (FTD-GRN), currently in Phase 1/2 ASPIRE-FTD clinical trial. The company also advances AVB-406 (tau gene silencing for Alzheimer's), UGX-202 (optogenetic therapy for retinitis pigmentosa), AVB-205 (ALS), and its proprietary vMiX RNAi platform for one-time, durable gene silencing across CNS and retinal indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to 80% MAPT mRNA knockdown in brain cortex tissue in humanized mice
+3 more records
Product overview1 text field

AviadoBio is a gene therapy company developing targeted, one-time AAV-based gene therapies for neurodegenerative disorders. The company's pipeline centers on AVB-101 (gene supplementation for FTD-GRN in Phase 1/2), AVB-406 (vMiX-powered RNAi for tau silencing in Alzheimer's disease, entering clinical stage), and UGX-202 (optogenetic therapy for retinitis pigmentosa in preclinical stage). The proprietary vMiX™ RNAi platform enables precision gene silencing with applications across multiple therapeutic areas. Delivery approaches include intrathalamic administration for brain targets, intravenous delivery with BBB-crossing capsids, and intravitreal delivery for retinal diseases.

Product and service1 record
1AVB-101
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-16
Description

Expanded exclusive license agreement providing AviadoBio rights to apply the vMiX RNAi gene silencing platform across all human therapeutic areas, extending beyond the original 2020 agreement focused on neurological diseases. The expansion opens potential applications across cardiovascular disease, nephrology, oncology and other indications. AviadoBio has been optimizing the vMiX platform since 2020 and developed an efficient discovery engine workflow for rapid progression of development candidates.

2UgeneX Therapeutics
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2025-10-10
Description

Agreement to license UGX-202, a gene therapy for retinitis pigmentosa, committing up to $413 million for development and sales milestones. The therapy uses an AAV viral vector to restore vision by reprogramming retinal cells and is set to enter clinical development. This expands AviadoBio's pipeline in genetic therapies for neurodegenerative and eye diseases.

biospace.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-08
Description

Exclusive option and license agreement for AVB-101, an investigational AAV-based gene therapy in Phase 1/2 development for frontotemporal dementia with progranulin mutations. AviadoBio received $20 million equity investment and up to $30 million in upfront payments, with potential milestone payments of up to $2.18 billion plus royalties if Astellas exercises its option. The collaboration combined AviadoBio's gene therapy expertise with Astellas' global development and commercialization capabilities. AviadoBio has since regained full worldwide rights to AVB-101 following expiration of Astellas' exclusive option in 2024.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage AAV gene therapy company focused on CNS diseases including Parkinson's, Huntington's, and Alzheimer's, with proprietary capsid engineering and RNAi approaches directly comparable to AviadoBio's vMiX platform and pipeline.

TypeDirect peer
Description

Clinical-stage AAV gene therapy developer with programs in Huntington's disease and ALS, sharing AviadoBio's AAV delivery approach and CNS neurodegenerative disease focus.

TypeDirect peer
Description

Clinical-stage gene therapy company with CNS and cardiac disease programs using AAV delivery, comparable in stage, modality, and target indications to AviadoBio's pipeline.

TypeDirect peer
Description

AAV gene therapy developer acquired by Eli Lilly with FTD-GRN and Parkinson's programs, directly competing with AVB-101 in the same indication with similar gene supplementation approach.

TypeDirect peer
Description

Clinical-stage AAV gene therapy company with CNS, ocular, and salivary gland programs, sharing AviadoBio's diversification across neurodegenerative and ophthalmology indications.

TypeDirect peer
Description

Genomic medicine company developing AAV-delivered gene therapies for CNS and rare diseases, comparable in modality and clinical-stage status to AviadoBio.

TypeBroad incumbent
Description

Large pharmaceutical company with significant neurodegenerative disease pipeline through Prevail Therapeutics acquisition, developing competing AAV gene therapy in FTD-GRN and broader Alzheimer's programs.

TypeBroad incumbent
Description

Large pharmaceutical company with gene therapy capabilities and CNS pipeline, overlapping with AviadoBio's neurodegenerative focus areas and representing both potential competitor and partner.

TypeOthers
Description

Former strategic partner of AviadoBio for AVB-101 with exclusive option that expired in 2024; a major CNS-focused pharmaceutical company that may re-engage or compete with similar gene therapy programs.

TypeEmerging player
Description

Bayer-owned cell and gene therapy company with Parkinson's and CNS programs using AAV and cell therapy approaches, representing an emerging competitor in neurodegenerative gene therapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AviadoBio

Gene Therapy for Neurodegenerative Diseasesaviadobio.com

AviadoBio is a London-based clinical-stage gene therapy company developing one-time AAV-based treatments for neurodegenerative disorders, including AVB-101 in Phase 1/2 for FTD-GRN, leveraging its proprietary vMiX RNAi silencing platform licensed from King's College London.

What AviadoBio does

AviadoBio is a London-headquartered, clinical-stage gene therapy company founded in 2019 to develop one-time, disease-modifying AAV-based treatments for neurodegenerative disorders with high unmet need. The company was spun out of King's College London and the UK Dementia Research Institute and operates with 11–50 employees across the UK and the United States. Its pipeline is anchored by AVB-101, an AAV gene supplementation therapy delivered via minimally invasive intrathalamic infusion that is currently in Phase 1/2 development (ASPIRE-FTD trial) for frontotemporal dementia with GRN mutations (FTD-GRN), and extends into AVB-406 (vMiX™ RNAi silencing of MAPT for Alzheimer's disease and tauopathies, preclinical with planned 2026 clinical entry), UGX-202 (an optogenetic AAV gene therapy for retinitis pigmentosa licensed from UgeneX Therapeutics in October 2025), and AVB-205 (an ATXN2-targeting preclinical construct for ALS).

AviadoBio's core technology is the proprietary vMiX™ vectorized RNAi gene silencing platform, exclusively licensed from King's College London and expanded in June 2026 to cover all human therapeutic areas. vMiX combines AAV-delivered RNAi payloads with cell- and tissue-specific promoters to enable one-time, durable silencing of up to three genes and supports silencing-and-replacement constructs. Delivery innovation includes the intrathalamic approach (leveraging the thalamus as a CNS relay hub for broad cortical expression of progranulin) and a BBB-penetrant AAV capsid using the human transferrin receptor 1 for systemic CNS exposure in AVB-406.

The company is pre-revenue and has no commercial products; its near-term economic model rests on milestone-based licensing and partnerships rather than product sales. Capital is sourced from an $80M seed round (December 2021), a $20M equity investment plus up to $30M upfront from Astellas under a now-lapsed exclusive option for AVB-101, strategic grants from the Alzheimer's Drug Discovery Foundation and the Association for Frontotemporal Degeneration, and contingent milestone payments from the UgeneX UGX-202 deal worth up to $413M. Go-to-market is enterprise-led: a Phase 1/2 clinical trial operating at multiple international sites, scientific-conference-driven visibility (ASGCT, AAIC, ESGCT, ISFTD), and a stated intent to pursue strategic partnerships to advance vMiX-enabled programs into cardiovascular, nephrology, oncology, and other newly licensed therapeutic areas.

AviadoBio firmographics

Firmographics
Name
AviadoBio
Legal name
AviadoBio Limited
Website
https://aviadobio.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
AviadoBio is a London-based clinical-stage gene therapy company developing one-time AAV-based treatments for neurodegenerative disorders, including AVB-101 in Phase 1/2 for FTD-GRN, leveraging its proprietary vMiX RNAi silencing platform licensed from King's College London.
Ownership category
akta.pro rank

AviadoBio industry classification

Industry
Product category
Gene Therapy for Neurodegenerative Diseases
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151)
akta.pro industry
PRIMARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAD
Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • AAV gene therapy
  • Neurodegenerative disease treatment
  • RNAi gene silencing
  • Frontotemporal dementia therapy
  • Central nervous system delivery

Where AviadoBio is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

AviadoBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Gene Therapy Development and Commercialization: As a clinical-stage biopharmaceutical company, AviadoBio is developing gene therapies for neurodegenerative diseases. The company has received strategic investments from ADDF and AFTD, and previously had an exclusive option agreement with Astellas worth up to $2.18 billion plus royalties. Revenue will come from commercialization of approved gene therapies.
  2. Platform Licensing and Partnerships: Expanded vMiX platform license with King's College London enables strategic collaborations and partnerships across cardiovascular disease, nephrology, oncology and other indications beyond the company's core neuroscience focus.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

AviadoBio product offering

Product offering

Core offering

AviadoBio is a clinical-stage gene therapy company developing investigational AAV-based, one-time gene therapies for neurodegenerative diseases. Its lead program, AVB-101, delivers a functional GRN gene via intrathalamic infusion for frontotemporal dementia with GRN mutations (FTD-GRN), currently in Phase 1/2 ASPIRE-FTD clinical trial. The company also advances AVB-406 (tau gene silencing for Alzheimer's), UGX-202 (optogenetic therapy for retinitis pigmentosa), AVB-205 (ALS), and its proprietary vMiX RNAi platform for one-time, durable gene silencing across CNS and retinal indications.

Product overview

AviadoBio is a gene therapy company developing targeted, one-time AAV-based gene therapies for neurodegenerative disorders. The company's pipeline centers on AVB-101 (gene supplementation for FTD-GRN in Phase 1/2), AVB-406 (vMiX-powered RNAi for tau silencing in Alzheimer's disease, entering clinical stage), and UGX-202 (optogenetic therapy for retinitis pigmentosa in preclinical stage). The proprietary vMiX™ RNAi platform enables precision gene silencing with applications across multiple therapeutic areas. Delivery approaches include intrathalamic administration for brain targets, intravenous delivery with BBB-crossing capsids, and intravitreal delivery for retinal diseases.

Differentiator

Problem solved

Functional benefit

Brands

  • vMiX™: Proprietary vectorized RNA interference (RNAi) gene silencing platform for one-time, durable gene silencing using AAV delivery

Products and services

  • AVB-101

Quantifiable outcome

  • Up to 80% MAPT mRNA knockdown in brain cortex tissue in humanized mice
  • +3 more outcomes

Companies that use AviadoBio

Customer profile

Segments4 records

Ideal customer profiles2 records

AviadoBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

AviadoBio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • King's College LondoncoreTechnology or Integration · 16 June 2026Expanded exclusive license agreement providing AviadoBio rights to apply the vMiX RNAi gene silencing platform across all human therapeutic areas, extending beyond the original 2020 agreement focused on neurological diseases. The expansion opens potential applications across cardiovascular disease, nephrology, oncology and other indications. AviadoBio has been optimizing the vMiX platform since 2020 and developed an efficient discovery engine workflow for rapid progression of development candidates.
  • UgeneX TherapeuticssupportingTechnology or Integration · 10 October 2025Agreement to license UGX-202, a gene therapy for retinitis pigmentosa, committing up to $413 million for development and sales milestones. The therapy uses an AAV viral vector to restore vision by reprogramming retinal cells and is set to enter clinical development. This expands AviadoBio's pipeline in genetic therapies for neurodegenerative and eye diseases.
  • Astellas PharmacoreStrategic or Co-development Partner · 8 October 2024Exclusive option and license agreement for AVB-101, an investigational AAV-based gene therapy in Phase 1/2 development for frontotemporal dementia with progranulin mutations. AviadoBio received $20 million equity investment and up to $30 million in upfront payments, with potential milestone payments of up to $2.18 billion plus royalties if Astellas exercises its option. The collaboration combined AviadoBio's gene therapy expertise with Astellas' global development and commercialization capabilities. AviadoBio has since regained full worldwide rights to AVB-101 following expiration of Astellas' exclusive option in 2024.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

AviadoBio competitors and assessment

Company assessment

Direct peers

  • Voyager Therapeutics: Clinical-stage AAV gene therapy company focused on CNS diseases including Parkinson's, Huntington's, and Alzheimer's, with proprietary capsid engineering and RNAi approaches directly comparable to AviadoBio's vMiX platform and pipeline.
  • uniQure: Clinical-stage AAV gene therapy developer with programs in Huntington's disease and ALS, sharing AviadoBio's AAV delivery approach and CNS neurodegenerative disease focus.
  • Lexeo Therapeutics: Clinical-stage gene therapy company with CNS and cardiac disease programs using AAV delivery, comparable in stage, modality, and target indications to AviadoBio's pipeline.
  • Prevail Therapeutics (Eli Lilly): AAV gene therapy developer acquired by Eli Lilly with FTD-GRN and Parkinson's programs, directly competing with AVB-101 in the same indication with similar gene supplementation approach.
  • MeiraGTx: Clinical-stage AAV gene therapy company with CNS, ocular, and salivary gland programs, sharing AviadoBio's diversification across neurodegenerative and ophthalmology indications.
  • Sangamo Therapeutics: Genomic medicine company developing AAV-delivered gene therapies for CNS and rare diseases, comparable in modality and clinical-stage status to AviadoBio.

Broad incumbents

  • Eli Lilly: Large pharmaceutical company with significant neurodegenerative disease pipeline through Prevail Therapeutics acquisition, developing competing AAV gene therapy in FTD-GRN and broader Alzheimer's programs.
  • Pfizer: Large pharmaceutical company with gene therapy capabilities and CNS pipeline, overlapping with AviadoBio's neurodegenerative focus areas and representing both potential competitor and partner.

Others

  • Astellas Pharma: Former strategic partner of AviadoBio for AVB-101 with exclusive option that expired in 2024; a major CNS-focused pharmaceutical company that may re-engage or compete with similar gene therapy programs.

Emerging players

  • BlueRock Therapeutics (Bayer): Bayer-owned cell and gene therapy company with Parkinson's and CNS programs using AAV and cell therapy approaches, representing an emerging competitor in neurodegenerative gene therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

AviadoBio social profiles

Digital presence

AviadoBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AviadoBio leadership team

Management profile

Number of profiles

Profiles8 records

AviadoBio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AviadoBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AviadoBio

What does AviadoBio do?

AviadoBio is a clinical-stage gene therapy company developing investigational AAV-based, one-time gene therapies for neurodegenerative diseases. Its lead program, AVB-101, delivers a functional GRN gene via intrathalamic infusion for frontotemporal dementia with GRN mutations (FTD-GRN), currently in Phase 1/2 ASPIRE-FTD clinical trial. The company also advances AVB-406 (tau gene silencing for Alzheimer's), UGX-202 (optogenetic therapy for retinitis pigmentosa), AVB-205 (ALS), and its proprietary vMiX RNAi platform for one-time, durable gene silencing across CNS and retinal indications.

Is AviadoBio a public or private company?

AviadoBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was AviadoBio founded?

AviadoBio was founded in 2019. It employs 51 to 100 people.

Where is AviadoBio based?

AviadoBio is headquartered in London, United Kingdom, in the Europe region.

How does AviadoBio make money?

Two revenue lines are on record. Gene Therapy Development and Commercialization is the primary driver. The others are platform Licensing and Partnerships.

Who are AviadoBio's main competitors?

Direct peers on record are Voyager Therapeutics, uniQure, Lexeo Therapeutics, Prevail Therapeutics (Eli Lilly), MeiraGTx and Sangamo Therapeutics. Broad incumbents are Eli Lilly and Pfizer. Astellas Pharma is listed as an others. BlueRock Therapeutics (Bayer) is listed as an emerging player.

Does AviadoBio have an API?

No public API is recorded for AviadoBio.

What industry is AviadoBio in?

AviadoBio's product category is Gene Therapy for Neurodegenerative Diseases. Its primary akta.pro industry code is HLAAACAH, Neurology/CNS Gene Therapies, with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAviadoBio Presents New Preclinical Data Validating the vMiX™ Platform for AVB-406 in Alzheimer’s Disease and for AVB-SNCA in Parkinson’s Disease at ESGCT 2026AviadoBio presented preclinical data at ESGCT 2026 showing AVB-406 maintains MAPT knockdown and reduces tau protein by 84% at six months in mice, with no adverse signs. AVB-SNCA achieved up to 80% SNCA silencing in human neurons, supporting development as a one-time therapy for Parkinson's disease. The company plans first-in-human studies for early Alzheimer's in 2027.Financial PostAviadoBio Presents New Safety and Biomarker Data from the Phase 1/2 ASPIRE-FTD Trial at the International Conference on Frontotemporal DementiasAviadoBio presented preliminary data from its ASPIRE-FTD trial at the International Conference on Frontotemporal Dementias, showing dose-dependent increases in CSF progranulin and serum neurofilament light chain at or below baseline. The gene therapy AVB-101 has been well tolerated with no serious adverse events. Enrollment in the fourth cohort is ongoing.FinancialContent Business PageAviadoBio Presents New Safety and Biomarker Data from the Phase 1/2 ASPIRE-FTD Trial at the International Conference on Frontotemporal DementiasAviadoBio presented preliminary data from its ASPIRE-FTD trial at the International Conference on Frontotemporal Dementias, showing dose-dependent increases in CSF progranulin across four ascending doses. Serum neurofilament light chain remained at or below baseline in all patients with 52-week data, and AVB-101 was well tolerated with no serious adverse events.Business Wire BlogAviadoBio Presents New Safety and Biomarker Data from the Phase 1/2 ASPIRE-FTD Trial at the International Conference on Frontotemporal DementiasAviadoBio presented preliminary data from its ASPIRE-FTD trial at the International Conference on Frontotemporal Dementias, showing dose-dependent increases in CSF progranulin across four ascending doses. The gene therapy AVB-101 has been well tolerated with no serious adverse events, and serum neurofilament light chain remained at or below baseline at 52 weeks.Neurology liveNewly Initiated ASPIRE-FTD Trial Opens Door for Gene Therapy to Treat Frontotemporal DementiaAviadoBio opened its ASPIRE-FTD phase 1/2 trial for AVB-101, a gene therapy for frontotemporal dementia with progranulin mutations. The one-time thalamic infusion aims to restore progranulin levels, with two doses and five-year follow-up. The company expects to demonstrate safety and identify an effective dose.Pharmaceutical TechnologyAviadoBio broadens vMiX gene silencing licence with King’s College LondonAviadoBio extended its exclusive vMiX RNAi gene-silencing licence with King's College London to all human therapeutic areas, beyond its prior neurological focus. The platform can target up to three genes and was shown to achieve up to 80% MAPT knockdown in preclinical data. The expansion enables partnerships in cardiovascular, nephrology, and oncology.FinancialContent Business PageAviadoBio Expands vMiX™ Precision Gene Silencing Platform Exclusive License Agreement with King’s College London Beyond Neurological Diseases to All Human Therapeutic AreasAviadoBio and King's College London announced an expanded license agreement granting AviadoBio exclusive rights to apply the vMiX™ RNAi gene silencing platform across all human therapeutic areas, extending beyond the original 2020 neurological disease focus to include cardiovascular disease, nephrology, oncology, and other indications. The expansion follows recent positive preclinical data for AVB-406 showing dose-dependent MAPT knockdown of up to 80% in the brain, presented at the ASGCT 2026 Annual Meeting. The company plans to initiate clinical trials for vMiX-enabled programs in 2026 and intends to pursue strategic partnerships to advance programs across the newly licensed therapeutic areas.Business Wire BlogAviadoBio Expands vMiX™ Precision Gene Silencing Platform Exclusive License Agreement with King’s College London Beyond Neurological Diseases to All Human Therapeutic AreasAviadoBio and King's College London expanded their vMiX RNAi platform license to all human therapeutic areas, beyond neurological diseases. The platform can silence up to three genes simultaneously, and preclinical data for AVB-406 showed up to 80% MAPT knockdown in Alzheimer's models.BioWorldAVB-406: AAV-miRNA targeting MAPT in Alzheimer’s diseaseResearchers at Aviadobio Ltd. presented AVB-406, an intravenously administered gene therapy using its vMiX RNAi platform to lower tau production and reduce neurofibrillary tangle formation. The therapy targets MAPT, aiming to reduce tau pathology in Alzheimer's disease and related disorders.BioSpaceAviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026AviadoBio presented positive preclinical data for AVB-406 at ASGCT 2026, showing up to 80% MAPT/tau knockdown in brain tissue. The data support planned clinical initiation for Alzheimer's disease by the end of 2026. The company aims to advance AVB-406 into first-in-human studies later this year.